4.7 out of 5 from our editorial team, backed by an industry-leading 4.7-star Trustpilot rating from 15,750+ reviews, 8-biomarker lab testing, dietitian and meal plan support, and a unique 10% weight loss guarantee with money-back promise
Tirzepatide represents a dual agonist, targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which may explain its enhanced efficacy in clinical trials
The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)
Some got as high as 20%
Additionally, tirzepatide effectively reduced glucose levels and had a similar safety profile to semaglutide
Contact your prescriber or clinical team if you notice: You're consistently eating fewer than 800 kcal per day for more than a week, despite trying to eat more Significant hair loss more than the usual shed, particularly from the crown or temples Persistent dizziness or light-headedness, especially on standing Extreme fatigue that is disproportionate to your activity level You cannot meet your protein minimum on most days, even with liquid nutrition and no-prep foods Nausea that prevents eating entirely for more than 2448 hours after injection These are not reasons to panic they are reasons to have a conversation